Indie Asset Partners LLC Grows Position in Eli Lilly and Company $LLY

Key Points

• Indie Asset Partners boosted its Eli Lilly stake by 25.2% in the fourth quarter, making LLY its largest position at 13.8% of the portfolio.
• Eli Lilly beat quarterly expectations, reporting EPS of $8.55 versus $6.97 expected and revenue of $19.8 billion versus $17.82 billion expected, with revenue up 55.5% year over year.
• Analysts remain broadly bullish on the stock: the consensus rating is “Moderate Buy,” with an average price target of $1,218.33, while the company also declared a quarterly dividend of $1.73 per share.

Indie Asset Partners LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 25.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,536 shares of the company's stock after acquiring an additional 2,322 shares during the quarter. Eli Lilly and Company comprises about 13.8% of Indie Asset Partners LLC's investment portfolio, making the stock its biggest position. Indie Asset Partners LLC's holdings in Eli Lilly and Company were worth $12,398,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after buying an additional 16 shares during the last quarter. 10Elms LLP grew its holdings in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares during the last quarter. Miller Global Investments LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $33,000. Finally, Hopwood Financial Services Inc. increased its position in Eli Lilly and Company by 113.6% in the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company's stock worth $36,000 after buying an additional 25 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 2.8%

Shares of LLY opened at $948.01 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a 50-day moving average price of $943.90 and a two-hundred day moving average price of $990.90. The stock has a market cap of $892.78 billion, a price-to-earnings ratio of 33.68, a P/E/G ratio of 1.04 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the company a "buy" rating in a research report on Friday, March 13th. Wolfe Research reiterated an "outperform" rating and set a $1,325.00 target price on shares of Eli Lilly and Company in a research note on Monday, May 4th. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a "buy" rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 2nd. Finally, Leerink Partners cut their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating for the company in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,218.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.